(0.18%) 5 140.75 points
(0.12%) 38 487 points
(0.27%) 17 894 points
(-0.48%) $83.45
(1.61%) $1.954
(0.09%) $2 349.40
(0.56%) $27.69
(1.41%) $935.10
(-0.03%) $0.934
(-0.13%) $11.01
(-0.15%) $0.799
(1.28%) $93.05
Live Chart Being Loaded With Signals
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug...
Stats | |
---|---|
今日成交量 | 84 900.00 |
平均成交量 | 69 440.00 |
市值 | 105.02B |
EPS | ¥0 ( 2024-02-05 ) |
下一个收益日期 | ( ¥0 ) 2024-05-08 |
Last Dividend | ¥32.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.63 |
ATR14 | ¥1.224 (0.07%) |
音量 相关性
KYORIN Holdings, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
KYORIN Holdings, Inc. 相关性 - 货币/商品
KYORIN Holdings, Inc. 财务报表
Annual | 2022 |
营收: | ¥113.27B |
毛利润: | ¥50.17B (44.29 %) |
EPS: | ¥82.42 |
FY | 2022 |
营收: | ¥113.27B |
毛利润: | ¥50.17B (44.29 %) |
EPS: | ¥82.42 |
FY | 2022 |
营收: | ¥105.53B |
毛利润: | ¥49.44B (46.85 %) |
EPS: | ¥68.62 |
FY | 2021 |
营收: | ¥102.90B |
毛利润: | ¥51.63B (50.17 %) |
EPS: | ¥106.99 |
Financial Reports:
No articles found.
KYORIN Holdings, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥32.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥10.00 | 2006-09-26 |
Last Dividend | ¥32.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 35 | -- |
Total Paid Out | ¥862.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.6 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.48 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6638.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
5965.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4662.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3902.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3134.T | Ex Dividend Junior | 2024-04-26 | Annually | 0 | 0.00% | |
2004.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9613.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8550.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7872.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7013.T | No Dividend Player | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0356 | 1.500 | 9.29 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0238 | 1.200 | 9.21 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0339 | 1.500 | -0.735 | -1.102 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.53 | 0.800 | 2.34 | 1.871 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.402 | 1.500 | 8.88 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.116 | -1.500 | 8.06 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 75.14 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.164 | -1.500 | 9.34 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.429 | 1.000 | 6.18 | 6.18 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0408 | 1.000 | -1.185 | -1.185 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.405 | 1.000 | 8.86 | 8.86 | [0.2 - 2] |
assetTurnoverTTM | 0.670 | 0.800 | 8.87 | 7.10 | [0.5 - 2] |
Total Score | 10.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.65 | 1.000 | 7.61 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0339 | 2.50 | -0.472 | -1.102 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.84 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.226 | 1.500 | 5.16 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0702 | 1.000 | -0.745 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
KYORIN Holdings, Inc.
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。